Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced EGFR L858R NSCLC.

被引：0
|
作者：
Zhao, Xinmin
Wu, Xianghua
Wang, Huijie
Yu, Hui
Sun, Si
Feng, Yu
Wang, Jialei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21185
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparison of the Efficacy of Dacomitinib v Erlotinib for NSCLC Pts with Del 19/L858R
    Ramalingam, Suresh S.
    O'Byrne, Kenneth J.
    Mok, Tony
    Boyer, Michael
    Jaenne, Pasi A.
    Goldberg, Zelanna
    Mather, Cecile B.
    Taylor, Ian
    Zhang, Hui
    Paz-Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S278 - S278
  • [22] Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
    Hou, Zhiwei
    Wu, Huaguo
    Luo, Ningning
    Li, Shuo
    Zhang, Xiang
    Dong, Shuai
    Zhu, Dongyuan
    Zhang, Hui
    Tao, Rongjie
    [J]. ONCOLOGIST, 2023, 28 (05): : 449 - 452
  • [23] Therapeutic effect of gefitinib on patients with advanced EGFR-mutation NSCLC
    Xu, Ailing
    Yan, Haixia
    Bu, Tongliang
    [J]. PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 34 (01) : 481 - 486
  • [24] COMPARISON OF THE EFFICACY OF GEFITINIB IN PATIENTS WITH NSCLC ACCORDING TO THE TYPE OF EGFR MUTATION
    Kasajima, Masashi
    Igawa, Satoshi
    Ishihara, Mikiko
    Kimura, Michiko
    Kusuhara, Seiichiro
    Harada, Sinya
    Hiyoshi, Yasuhiro
    Katono, Ken
    Sasaki, Jiichiro
    Masuda, Noriyuki
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [25] Associations between chromosome 7 aneusomy and EGFR copy number with survival and response to gefitinib in NSCLC.
    Morrison, L. E.
    Jewell, S. S.
    Jacobson, K. K.
    Kaiser, K.
    Gale, M.
    Muzzafar, T.
    Mauer, A. M.
    Villaflor, V. M.
    Bonomi, P.
    Coon, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 406S - 406S
  • [26] Neoantigen screening identifies EGFR L858R mutation immunogenicity in 1862 Chinese NSCLC patients.
    Lin, Jin
    Chen, Yu
    Chen, Gang
    Jun, Liu
    Hao, Shiguang
    Xiong, Jia-ni
    Lan, Bin
    Xu, Yaping
    Guan, Yan-Fang
    Guo, Zengqing
    Chen, Lin
    Chen, Li-zhu
    Xia, Xuefeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Effect of bevacizumab plus double dose icotinib on advanced non-small cell lung cancer with EGFR L858R mutation
    Jiang, Zhansheng
    Li, Yong
    Yan, Zhuchen
    Lan, Lan
    Zhang, Xinwei
    Ren, Baozhu
    Wang, Fei
    Zhang, Wencheng
    Pan, Zhanyu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis
    Zhuo, Minglei
    Zheng, Qiwen
    Zhao, Jun
    Wu, Meina
    An, Tongtong
    Wang, Yuyan
    Li, Jianjie
    Wang, Shuhang
    Zhong, Jia
    Yang, Xue
    Chen, Hanxiao
    Jia, Bo
    Dong, Zhi
    Gao, Emei
    Wang, Jingjing
    Wang, Ziping
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (06) : 553 - +
  • [29] Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib:a propensity score matching analysis
    Minglei Zhuo
    Qiwen Zheng
    Jun Zhao
    Meina Wu
    Tongtong An
    Yuyan Wang
    Jianjie Li
    Shuhang Wang
    Jia Zhong
    Xue Yang
    Hanxiao Chen
    Bo Jia
    Zhi Dong
    Emei Gao
    Jingjing Wang
    Ziping Wang
    [J]. Chinese Journal of Cancer Research, 2017, 29 (06) : 553 - 560
  • [30] Gefitinib retreatment beyond progression in advanced NSCLC patients with sensitive EGFR mutations
    Sun, L.
    Tu, L.
    Wei, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345